The Bispecific Antibody: A Lethal Hybrid

Amgen’s acute lymphoblastic leukemia treatment, Blincyto, coasted past the FDA bottleneck ahead of schedule, gaining approval earlier this month as a “first of its kind” immunotherapy. The FDA designated Blincyto as a breakthrough therapy and an orphan product on top...